Across TCGA pan-cancer cohorts, MRPL38 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated MRPL38 data layer compared with 21 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher MRPL38 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated MRPL38 expression acts as an unfavorable survival marker.

BRCA, LUAD, and PCPG are the cancer types where MRPL38 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	DFS	Median	All	0.468	0.903	<.001	36	view →
LUAD	OS	Median	II,III,IV	0.113	0.709	<.001	12	view →
PCPG	DFS	Median	All	0.063	0.924	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: MRPL38 tumor-vs-normal RNA expression · all MRPL38 data types